Glaucoma

Iantrek announced it closed $23 million in Series B financing that will go toward initiating clinical trials of its MIGS devices, according to a press release.

One of the most common questions I get asked by my patients with glaucoma is, “Doc, what else can I do to help my disease and prevent blindness?”

Ocular hypertension is a risk factor for glaucoma, but in the absence of any glaucomatous damage it does not necessitate medical intervention.

Glaukos and iVeena Delivery Systems have entered into a strategic licensing agreement that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for the treatment of keratoconus, according to a press release.

Sight Sciences has launched Sion, a bladeless device used to perform goniotomy.

A genetic association study using two-sample Mendelian randomization analysis was able to demonstrate a shared genetic basis and an association between myopic refractive error and the risk for primary open-angle glaucoma.

The first patient has been enrolled in a prospective, randomized, multicenter study of the iTrack Advance canaloplasty device, according to a press release from Nova Eye Medical.

Nova Eye Medical has established the iTrack Global Data Registry, which will collect prospective data on canaloplasty in the treatment of glaucoma, according to a press release.

Black patients had a higher risk for developing advanced visual field loss after a new diagnosis of primary open-angle glaucoma, according to a study.

Add-on low-dose prednisolone improves long-term disease activity and progression in senior patients with established rheumatoid arthritis, albeit with an increase in non-severe adverse events, according to data.